{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T13:52:54Z","timestamp":1772632374437,"version":"3.50.1"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2025J011193"],"award-info":[{"award-number":["2025J011193"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the patterns of lymph node metastasis (LNM) in patients with thoracic esophageal squamous cell carcinoma (TESCC) treated with neoadjuvant immunochemotherapy (nICT) versus neoadjuvant chemotherapy (nCT) alone and its impact on prognosis and potential clinical implications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A single-center retrospective cohort study was conducted on 441 patients with locally advanced TESCC who underwent nCT (n=179) or nICT (n=262) followed by esophagectomy. LNM patterns were analyzed according to the Japanese Classification of Esophageal Cancer (12\n                      <jats:sup>th<\/jats:sup>\n                      Edition), using metrics including lymph node ratio (LNR), lymph node metastasis rate and actual lymph node metastasis rate for specific stations. Postoperative recurrence patterns, overall survival (OS), and event-free survival (EFS) were also evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compared with nCT, nICT achieved a significantly higher pathological complete response (pCR) rate (22.1% vs. 6.7%,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001) and a lower metastatic lymph node ratio (LNR) (3.5% vs 6.2%,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001). Although the overall LNM rate was similar between groups, nICT demonstrated reduced lymph node involvement in several key station lymph nodes, particularly level 7 (along the left gastric artery), with lower the lymph node metastasis rate (LNMR2) (7.6% vs. 14.5%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.020) and the actual metastasis rate (LNMR3) (8.4% vs. 16.8%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.012). The overall recurrence\/metastasis rate was significantly lower in the nICT group (36.2% vs. 56.8%,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001), with a notable reduction of recurrence at the anastomotic site. In multivariable analyses, nICT independently predicted lower recurrence risk (adjusted OR = 0.55,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.013) and improved EFS (HR = 0.65,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.001) while OS was not statistically different between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In comparison to nCT alone, nICT was significantly associated with deeper pathological response, lower LNM burden, and reduced postoperative recurrence in TESCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1762746","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:00:03Z","timestamp":1772607603000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Analyses on patterns of lymph node metastasis and its impact on prognosis in thoracic esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy versus chemotherapy alone: a single-center, retrospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Weibin","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, National Health Commission (NHC) Key Laboratory of Cancer Metabolism","place":["Fuzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujie","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital of Fujian Medical University","place":["Fuzhou, Fujian, China"]},{"name":"Department of Medical Oncology, Fuzhou Hospital of Traditional Chinese Medicine affiliated to Fujian University of Traditional Chinese Medicine","place":["Fuzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Interdisciplinary Institute of Medical Engineering of Fuzhou University","place":["Fuzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weikun","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, National Health Commission (NHC) Key Laboratory of Cancer Metabolism","place":["Fuzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianqing","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijin","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, National Health Commission (NHC) Key Laboratory of Cancer Metabolism","place":["Fuzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijin","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, National Health Commission (NHC) Key Laboratory of Cancer Metabolism","place":["Fuzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, National Health Commission (NHC) Key Laboratory of Cancer Metabolism","place":["Fuzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiarong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, National Health Commission (NHC) Key Laboratory of Cancer Metabolism","place":["Fuzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weimin","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, National Health Commission (NHC) Key Laboratory of Cancer Metabolism","place":["Fuzhou, China"]},{"name":"Interdisciplinary Institute of Medical Engineering of Fuzhou University","place":["Fuzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, National Health Commission (NHC) Key Laboratory of Cancer Metabolism","place":["Fuzhou, China"]},{"name":"Interdisciplinary Institute of Medical Engineering of Fuzhou University","place":["Fuzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-023-2423-1","article-title":"Cancer profiles in China and comparisons with the USA: a comprehensive analysis in the incidence, mortality, survival, staging, and attribution to risk factors","volume":"67","author":"He","year":"2024","journal-title":"Sci China Life Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(23)00211-6","article-title":"National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data","volume":"8","author":"Qi","year":"2023","journal-title":"Lancet Public Health"},{"key":"B4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2024.06.005","article-title":"Cancer survival statistics in China 2019\u20132021: a multicenter, population-based study","volume":"4","author":"Zeng","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308124","article-title":"Global incidence of oesophageal cancer by histological subtype in 2012","volume":"64","author":"Arnold","year":"2015","journal-title":"Gut"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321600","article-title":"Global burden of oesophageal and gastric cancer by histology and subsite in 2018","volume":"69","author":"Arnold","year":"2020","journal-title":"Gut"},{"key":"B8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3978\/j.issn.2305-5839.2015.11.05","article-title":"Prognostic factors in patients with thoracic esophageal carcinoma staged pT1-4aN0M0 undergone esophagectomy with three-field lymphadenectomy","volume":"3","author":"Chen","year":"2015","journal-title":"Ann Transl Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12922","article-title":"Lymphovascular invasion as an independent prognostic indicator in radically resected thoracic esophageal squamous cell carcinoma","volume":"10","author":"Wang","year":"2019","journal-title":"Thorac CA"},{"key":"B10","doi-asserted-by":"publisher","first-page":"238","DOI":"10.21037\/atm.2019.04.64","article-title":"Salvage lymphadenectomy for isolated cervical lymph node recurrence after curative resection of thoracic esophageal squamous cell carcinoma","volume":"7","author":"Wang","year":"2019","journal-title":"Ann Transl Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/dote\/doad006","article-title":"Lymph node metastatic patterns and the development of multidisciplinary treatment for esophageal cancer","volume":"36","author":"Matsuda","year":"2023","journal-title":"Dis Esoph"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2013.07.006","article-title":"Prevalence of lymph node metastases in superficial esophageal squamous cell carcinoma","volume":"146","author":"Li","year":"2013","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.07.42","article-title":"The extent of lymphadenectomy in esophageal resection for cancer should be standardized","volume":"9","author":"Hagens","year":"2017","journal-title":"J Thorac Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07393-w","article-title":"Nomogram to predict overall survival for thoracic esophageal squamous cell carcinoma patients after radical esophagectomy","volume":"26","author":"Deng","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e0185424","DOI":"10.1371\/journal.pone.0185424","article-title":"Patterns and rates of abdominal lymphatic metastasis following esophageal carcinoma","volume":"12","author":"Chen","year":"2017","journal-title":"PloS One"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14892","article-title":"Proposed modifications of supraclavicular lymph node metastasis in the esophageal squamous cell carcinoma staging system for improved survival stratification","volume":"8","author":"Zheng","year":"2017","journal-title":"Oncotarget"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2022.08.009","article-title":"Prognostic value of recurrence pattern in locally advanced esophageal squamous cell carcinoma: Results from the phase III trial NEOCRTEC5010","volume":"165","author":"Chen","year":"2023","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/jco.20.03614","article-title":"Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial","volume":"39","author":"Eyck","year":"2021","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0000000000005533","article-title":"Real-world evaluation of the efficacy of neoadjuvant DCF over CF in esophageal squamous cell carcinoma: propensity score\u2013matched analysis from 85 authorized institutes for esophageal cancer in Japan","volume":"278","author":"Matsuda","year":"2023","journal-title":"Ann Surg"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.1483","article-title":"Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): A phase III multicenter, randomized, open-label clinical trial","volume":"36","author":"Yang","year":"2018","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.2373","article-title":"Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial","volume":"156","author":"Yang","year":"2021","journal-title":"JAMA Surg"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14069","article-title":"History and current situation of neoadjuvant treatment for locally advanced esophageal cancer","volume":"12","author":"Li","year":"2021","journal-title":"Thorac CA"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/s0140-6736(24)02226-8","article-title":"Oesophageal cancer","volume":"404","author":"Yang","year":"2024","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"9676","DOI":"10.1038\/s41467-025-64660-z","article-title":"Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO)","volume":"16","author":"Wang","year":"2025","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13014-019-1258-4","article-title":"Proposed revision of the 8th edition AJCC clinical staging system for esophageal squamous cell cancer treated with definitive chemo-IMRT based on CT imaging","volume":"14","author":"Chen","year":"2019","journal-title":"Radiat Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13014-018-1086-y","article-title":"Adjuvant chemotherapy does not benefit patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy","volume":"13","author":"Chen","year":"2018","journal-title":"Radiat Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jtho.2016.10.016","article-title":"Cancer of the esophagus and esophagogastric junction: an eighth edition staging primer","volume":"12","author":"Rice","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10388-024-01054-y","article-title":"Japanese classification of esophageal cancer, 12th edition: part I","volume":"21","author":"Mine","year":"2024","journal-title":"Esophagus"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11660","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy","volume":"98","author":"Becker","year":"2003","journal-title":"Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2025.110138","article-title":"The prognostic value of circumferential resection margin (CRM) definition and location in esophageal cancer: A 12-year cohort study","volume":"51","author":"Elshaer","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12131","article-title":"Prognostic role of the lymph node ratio in node positive colorectal cancer: a meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0000000000003499","article-title":"Mapping of lymph node metastasis from esophagogastric junction tumors: A prospective nationwide multicenter study","volume":"274","author":"Kurokawa","year":"2021","journal-title":"Ann Surg"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1668649","article-title":"Analysis of lymph node recurrence patterns and risk factors in locally advanced esophageal carcinoma following neoadjuvant therapy","volume":"15","author":"Liu","year":"2025","journal-title":"Front Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.11.6999","article-title":"Supraclavicular lymph nodes detected by 18F-FDG PET\/CT in cancer patients: assessment with 18F-FDG PET\/CT and sonography","volume":"198","author":"Lee","year":"2012","journal-title":"AJR Am J Roentgenol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1007\/s12672-025-03657-y","article-title":"Neoadjuvant immunochemotherapy versus chemotherapy alone for locally advanced esophageal squamous cell carcinoma: a real-world retrospective study","volume":"16","author":"Zhou","year":"2025","journal-title":"Discov Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezaf268","article-title":"Comparative efficacy and safety of neoadjuvant immunochemotherapy versus chemotherapy in locally advanced oesophageal squamous cell carcinoma: A dual-centre retrospective study","volume":"67","author":"Ge","year":"2025","journal-title":"Eur J Cardiothorac Surg"},{"key":"B37","unstructured":"FDA approves pembrolizumab for esophageal or GEJ carcinoma\n          \n          2021"},{"key":"B38","unstructured":"FDA approves nivolumab for resected esophageal or GEJ cancer\n          \n          2021"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.11.039","article-title":"Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)","volume":"144","author":"Li","year":"2021","journal-title":"Eur J CA"},{"key":"B40","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1186\/s12885-022-09573-6","article-title":"Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 Study)","volume":"22","author":"Yang","year":"2022","journal-title":"BMC CA"},{"key":"B41","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jtcvs.2023.08.056","article-title":"Two-year outcomes of clinical N2\u20133 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study","volume":"167","author":"Yang","year":"2024","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B42","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-025-02477-4","article-title":"Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1\/2 trial (PALACE-2)","volume":"10","author":"Li","year":"2025","journal-title":"Signal Transduct Targ Ther"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e093538","DOI":"10.1136\/bmjopen-2024-093538","article-title":"Neoadjuvant camrelizumab combined with chemoradiotherapy and watch-and-wait strategy versus neoadjuvant chemoradiotherapy followed by surgery in locally advanced oesophageal squamous cell carcinoma: study protocol of a randomised controlled trial (PALACE-3)","volume":"15","author":"Wang","year":"2025","journal-title":"BMJ Open"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.70214","article-title":"Efficacy of adjuvant immunotherapy and immunochemotherapy in esophageal squamous cell carcinoma: A retrospective cohort study","volume":"158","author":"Jiang","year":"2025","journal-title":"Int J Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","article-title":"Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Obermannov\u00e1","year":"2022","journal-title":"Ann Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0244","article-title":"Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: A review of current evidence","volume":"25","author":"Klempner","year":"2020","journal-title":"Oncologist"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03064-w","article-title":"Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial","volume":"30","author":"Qin","year":"2024","journal-title":"Nat Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1762746\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:00:30Z","timestamp":1772607630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1762746\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2026.1762746"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1762746","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"article-number":"1762746"}}